IGC Pharma annual revenue
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2025
IGC Pharma Revenue Growth & History (IGC)
IGC Pharma reported $869,000 in revenue for fiscal 2025.
View full IGC Pharma company overviewIGC Pharma annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 · Dec 31 | 2025-12-31 | $869,000 | — | — |
| 2025 · Mar 31 | 2025-03-31 | $1.3M | −$74,000 | −5.50% |
| 2024 | 2024-03-31 | $1.3M | $434,000 | +47.64% |
| 2023 | 2023-03-31 | $911,000 | $622,000 | +215.22% |
| 2022 | 2022-03-31 | $289,000 | −$609,000 | −67.82% |
| 2021 | 2021-03-31 | $898,000 | −$3.2M | −77.95% |
| 2020 | 2020-03-31 | $4.1M | −$1.0M | −20.41% |
| 2019 | 2019-03-31 | $5.1M | $2.9M | +133.29% |
| 2018 | 2018-03-31 | $2.2M | $1.6M | +277.86% |
| 2017 | 2017-03-31 | $580,372 | −$5.8M | −90.88% |
| 2016 | 2016-03-31 | $6.4M | −$1.3M | −17.10% |
| 2015 | 2015-03-31 | $7.7M | $5.4M | +237.87% |
| 2014 | 2014-03-31 | $2.3M | −$5.8M | −71.69% |
| 2013 | 2013-03-31 | $8.0M | $3.8M | +91.21% |
| 2012 | 2012-03-31 | $4.2M | $125,632 | +3.08% |
| 2011 | 2011-03-31 | $4.1M | — | — |
IGC Pharma quarterly revenue
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 · Jun 30 | 2026-06-30 | $265,000 | −$63,000 | −19.21% |
| Q1 2026 · Mar 31 | 2026-03-31 | $317,000 | −$13,000 | −3.94% |
| Q4 2025 | 2025-12-31 | $20,000 | −$237,000 | −92.22% |
| Q2 2026 · Sep 30 | 2025-09-30 | $191,000 | −$221,000 | −53.64% |
| Q1 2026 · Jun 30 | 2025-06-30 | $328,000 | $56,000 | +20.59% |
| Q4 2025 | 2025-03-31 | $330,000 | $35,000 | +11.86% |
| Q3 2025 | 2024-12-31 | $257,000 | $53,000 | +25.98% |
| Q2 2025 | 2024-09-30 | $412,000 | $121,000 | +41.58% |
| Q1 2025 | 2024-06-30 | $272,000 | −$283,000 | −50.99% |
| Q4 2024 | 2024-03-31 | $295,000 | $130,000 | +78.79% |
| Q3 2024 | 2023-12-31 | $204,000 | −$128,000 | −38.55% |
| Q2 2024 | 2023-09-30 | $291,000 | $89,000 | +44.06% |
| Q1 2024 | 2023-06-30 | $555,000 | $343,000 | +161.79% |
| Q4 2023 | 2023-03-31 | $165,000 | $151,000 | +1078.57% |
| Q3 2023 | 2022-12-31 | $332,000 | $190,000 | +133.80% |
| Q2 2023 | 2022-09-30 | $202,000 | $146,000 | +260.71% |
| Q1 2023 | 2022-06-30 | $212,000 | $135,000 | +175.32% |
| Q4 2022 | 2022-03-31 | $14,000 | −$67,000 | −82.72% |
| Q3 2022 | 2021-12-31 | $142,000 | $34,000 | +31.48% |
| Q2 2022 | 2021-09-30 | $56,000 | −$69,000 | −55.20% |
| Q1 2022 | 2021-06-30 | $77,000 | −$507,000 | −86.82% |
| Q4 2021 | 2021-03-31 | $81,000 | $52,000 | +179.31% |
| Q3 2021 | 2020-12-31 | $108,000 | −$465,000 | −81.15% |
| Q2 2021 | 2020-09-30 | $125,000 | −$1.7M | −93.14% |
| Q1 2021 | 2020-06-30 | $584,000 | −$1.1M | −64.58% |
| Q4 2020 | 2020-03-31 | $29,000 | −$1.5M | −98.12% |
| Q3 2020 | 2019-12-31 | $573,000 | −$712,000 | −55.41% |
| Q2 2020 | 2019-09-30 | $1.8M | $1.0M | +124.54% |
| Q1 2020 | 2019-06-30 | $1.6M | $171,000 | +11.57% |
| Q4 2019 | 2019-03-31 | $1.5M | $398,926 | +34.90% |
| Q3 2019 | 2018-12-31 | $1.3M | $523,000 | +68.64% |
| Q2 2019 | 2018-09-30 | $811,000 | $576,000 | +245.11% |
| Q1 2019 | 2018-06-30 | $1.5M | $1.4M | +2692.58% |
| Q4 2018 | 2018-03-31 | $1.1M | $1.3M | +1051.89% |
| Q3 2018 | 2017-12-31 | $762,000 | $512,199 | +205.04% |
| Q2 2018 | 2017-09-30 | $235,000 | $72,837 | +44.92% |
| Q1 2018 | 2017-06-30 | $52,926 | −$235,567 | −81.65% |
| Q4 2017 | 2017-03-31 | −$120,085 | −$1.5M | −108.78% |
| Q3 2017 | 2016-12-31 | $249,801 | −$835,199 | −76.98% |
| Q2 2017 | 2016-09-30 | $162,163 | −$1.9M | −92.11% |
| Q1 2017 | 2016-06-30 | $288,493 | −$1.6M | −84.48% |
| Q4 2016 | 2016-03-31 | $1.4M | −$889,229 | −39.41% |
| Q3 2016 | 2015-12-31 | $1.1M | −$1.5M | −57.32% |
| Q2 2016 | 2015-09-30 | $2.1M | −$62,231 | −2.94% |
| Q1 2016 | 2015-06-30 | $1.9M | $1.1M | +143.34% |
| Q4 2015 | 2015-03-31 | $2.3M | $2.3M | +121215.67% |
| Q3 2015 | 2014-12-31 | $2.5M | $2.5M | +14402.78% |
| Q2 2015 | 2014-09-30 | $2.1M | $984,231 | +86.82% |
| Q1 2015 | 2014-06-30 | $763,864 | −$360,040 | −32.03% |
| Q4 2014 | 2014-03-31 | −$1,863 | −$1.5M | −100.13% |
| Q3 2014 | 2013-12-31 | $17,529 | −$3.9M | −99.55% |
| Q2 2014 | 2013-09-30 | $1.1M | −$217,881 | −16.12% |
| Q1 2014 | 2013-06-30 | $1.1M | −$143,776 | −11.34% |
| Q4 2013 | 2013-03-31 | $1.5M | $236,580 | +19.07% |
| Q3 2013 | 2012-12-31 | $3.9M | $2.9M | +298.65% |
| Q2 2013 | 2012-09-30 | $1.4M | $439,345 | +48.17% |
| Q1 2013 | 2012-06-30 | $1.3M | $207,433 | +19.56% |
| Q4 2012 | 2012-03-31 | $1.2M | $460,568 | +59.06% |
| Q3 2012 | 2011-12-31 | $986,799 | $502,693 | +103.84% |
| Q2 2012 | 2011-09-30 | $912,121 | −$769,465 | −45.76% |
| Q1 2012 | 2011-06-30 | $1.1M | −$68,164 | −6.04% |
| Q4 2011 | 2011-03-31 | $779,816 | — | — |
| Q3 2011 | 2010-12-31 | $484,106 | — | — |
| Q2 2011 | 2010-09-30 | $1.7M | — | — |
| Q1 2011 | 2010-06-30 | $1.1M | — | — |
IGC Pharma revenue growth trends
IGC Pharma's latest reported quarter, Q2 2026 · Jun 30, generated $265,000 in revenue, a decrease of 19.21% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review IGC Pharma source filings ↗